Clinical Trial Update: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study [Phase 2]

View source ↗

Summary

Phase 2 trial update on Prima BioMed's ovarian cancer vaccine for patients who progressed during CAN-003, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Ovarian cancer vaccine (CAN-003)

Snippet

Sponsor: Prima BioMed Ltd | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-12-08